Following up on a study originally published in Grey Horizon on December 18, 2012, researchers at the Ohio State University Comprehensive Cancer Center and MD Anderson Cancer Center have shown, in two clinical studies, that ibrutinib has "real potential as a safe, effective targeted treatment for adults with chronic lymphocytic leukemia (CLL) and for patients with mantle cell lymphoma (MCL)."
To read the complete press release, click here
Study mentioned: Byrd JC et al. Targeting BTK with Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013 Jun 19 [Epub ahead of print]. PMID: 23782158
No comments:
Post a Comment